Related Experiment Video
Updated: Aug 11, 2026
A Protocol for Detecting and Scavenging Gas-phase Free Radicals in Mainstream Cigarette Smoke
Published on: January 2, 2012
Antibody-catalyzed oxidative degradation of nicotine using riboflavin
Tobin J Dickerson1, Noboru Yamamoto, Kim D Janda
1Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute 10550 North Torrey Pines Road La Jolla, CA 92037, USA.
Abstract:
Tobacco abuse remains a major cause of death worldwide despite ample evidence linking nicotine to various disease states. Consequently, immunopharmacotherapeutic approaches for the treatment of nicotine abuse have received increasing attention. Although a number of nicotine-binding antibodies have been disclosed, no antibody catalysts exist which efficiently degrade nicotine into pharmacologically inactive substances. Herein, we report the first catalytic antibodies which can oxidatively degrade nicotine. These biocatalysts use the micronutrient riboflavin and visible light as a source of singlet oxygen for the production of reactive oxygen species. Along with various known nicotine metabolites, antibody-catalyzed nicotine oxidations produce two novel nicotine oxidation products that were also detected in control ozonation reactions of nicotine. The reaction is efficient, with multiple turnovers of catalyst observed and total consumption of nicotine attained. These results demonstrate the potential of harnessing riboflavin as an endogenous sensitizer for antibody-catalyzed oxidations and demonstrate a new approach for the development of an active vaccine for the treatment of nicotine addiction using in vivo catalytically active antibodies.
Insights
Researchers developed the first catalytic antibodies that break down nicotine. Using riboflavin and light, these biocatalysts offer a novel approach for nicotine addiction vaccines.
Area of Science:
- Biocatalysis and Immunopharmacology
- Oxidative Degradation of Nicotine
Background:
- Tobacco abuse is a leading global cause of death.
- Existing nicotine-binding antibodies do not efficiently degrade nicotine.
- Need for novel immunopharmacotherapeutic strategies against nicotine addiction.
Purpose of the Study:
- To develop the first catalytic antibodies capable of efficiently degrading nicotine.
- To explore the use of riboflavin and visible light for antibody-catalyzed nicotine oxidation.
- To investigate a new vaccine strategy for nicotine addiction treatment.
Main Methods:
- Development of catalytic antibodies for nicotine degradation.
- Utilizing riboflavin and visible light to generate singlet oxygen for reactive oxygen species production.
- Analysis of nicotine metabolites using mass spectrometry, including comparison with ozonation controls.
Main Results:
- Successfully generated catalytic antibodies that oxidatively degrade nicotine.
- Identified two novel nicotine oxidation products, alongside known metabolites.
- Demonstrated efficient catalytic activity with multiple turnovers and complete nicotine consumption.
Conclusions:
- Riboflavin can serve as an endogenous sensitizer for antibody-catalyzed oxidations.
- Catalytic antibodies offer a promising new approach for treating nicotine addiction.
- Potential for developing active vaccines utilizing in vivo catalytically active antibodies.
Related Concept Videos
02:23Autoxidation of Ethers to Peroxides and Hydroperoxides
01:17Oxidation of Phenols to Quinones
o-hydroxy phenols are oxidized to o-quinones and p-hydroxy phenols to p-quinones. Such redox reactions involve the transfer of two electrons and two protons. The reversible redox property is crucial in...
01:20Radical Autoxidation
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:25Bioactivation and Tissue Toxicity